AU2022336441A1 - Thiadiazolone derivatives useful as ampk activator - Google Patents

Thiadiazolone derivatives useful as ampk activator Download PDF

Info

Publication number
AU2022336441A1
AU2022336441A1 AU2022336441A AU2022336441A AU2022336441A1 AU 2022336441 A1 AU2022336441 A1 AU 2022336441A1 AU 2022336441 A AU2022336441 A AU 2022336441A AU 2022336441 A AU2022336441 A AU 2022336441A AU 2022336441 A1 AU2022336441 A1 AU 2022336441A1
Authority
AU
Australia
Prior art keywords
compound
methyl
oxo
chlorophenyl
thiadiazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022336441A
Other languages
English (en)
Inventor
Thomas Edlund
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of AU2022336441A1 publication Critical patent/AU2022336441A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
AU2022336441A 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator Pending AU2022336441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2112529.9A GB202112529D0 (en) 2021-09-02 2021-09-02 New compounds
GB2112529.9 2021-09-02
PCT/GB2022/052234 WO2023031609A1 (en) 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator

Publications (1)

Publication Number Publication Date
AU2022336441A1 true AU2022336441A1 (en) 2024-03-07

Family

ID=78076730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022336441A Pending AU2022336441A1 (en) 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator

Country Status (11)

Country Link
US (1) US20250136563A1 (enExample)
EP (1) EP4396171A1 (enExample)
JP (1) JP2024535745A (enExample)
KR (1) KR20240055039A (enExample)
CN (1) CN118510762A (enExample)
AU (1) AU2022336441A1 (enExample)
CA (1) CA3230307A1 (enExample)
GB (1) GB202112529D0 (enExample)
IL (1) IL310871A (enExample)
MX (1) MX2024002674A (enExample)
WO (1) WO2023031609A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
KR101889993B1 (ko) * 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds

Also Published As

Publication number Publication date
US20250136563A1 (en) 2025-05-01
IL310871A (en) 2024-04-01
EP4396171A1 (en) 2024-07-10
CA3230307A1 (en) 2023-03-09
WO2023031609A1 (en) 2023-03-09
CN118510762A (zh) 2024-08-16
JP2024535745A (ja) 2024-10-02
MX2024002674A (es) 2024-03-19
KR20240055039A (ko) 2024-04-26
GB202112529D0 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
AU784007B2 (en) Inhibitors of dipeptidyl peptidase IV
EP4222147B1 (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
AU2016253911B2 (en) Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof
KR20050072809A (ko) 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
US12391661B2 (en) Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
CN114380801A (zh) 氨基嘧啶ssao抑制剂及其制备方法
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20230141981A1 (en) Novel compounds and composition for targeted therapy of kidney-associated cancers
JP2009190971A (ja) ２−シアノピロリジン誘導体
JP2024506715A (ja) ソマトスタチンモジュレーターの結晶形態
RU2481341C2 (ru) Кристаллические модификации 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона
FI83525C (fi) Foerfarande foer att framstaella en farmakologiskt vaerdefull 1-metyl-4,5-dihydro-orotylhistidyl-prolinamid.
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
US20060135558A1 (en) Aroyl-piperidine derivatives
CN115003653A (zh) 艾拉菲诺的多晶型物
WO1993007886A1 (en) Pharmaceutical composition containing certain peptidomimetic compounds
ZA200302030B (en) Aliphatic nitrogen-containing 5-membered ring compound.
EP0387074A2 (en) Novel oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
HK1087998A (en) Variously substituted derivatives of guanidine, and their use as medicines with antidiabetes and/or anti-obesity activity